The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | Surgery assessment for patients with locally resectable NSCLC
Akif Turna, MD, PhD, Istanbul University-Cerrahpasa, Istanbul, Turkey, outlines the assessment of patients for locally resectable non-small cell lung cancer (NSCLC). Surgery in select patients with stage IA-IIIA NSCLC demonstrate positive survival rates, demonstrating the need for patients to be assessed before choosing a procedure. The assessment for surgery includes TNM classification, staging, and physiological evaluations. Evaluating patients is currently challenging due to the lack of established guidelines and decision-making criteria. Prof. Turna emphasises the importance of assessing patients with resectable NSCLC thoroughly in order to choose the most appropriate procedure. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
